Poster Listing


  1. A Canine Hemangiosarcoma Xenograft Angiogenesis Model
    Stuart Helfand, N. Akhtar, M.L. Padilla, EB Dickerson, H. Steinberg
  2. Von Willebrand Factor Antigen may be a Surrogate Marker for Biological Effect on Endothelial Cells in Patients with Solid Tumors Treated with Anti-Angiogenesis Compounds
    Paul Masci, S. Radka, C. Pasco, R. Aitchison, V. Parker, N. Usman, E.C. Borden, D. Weng
  3. Quantification of Angiogenesis by Functional Computed Tomography (fCT) in a Rat Model
    Sith Phongkitkarun, S. Kobayashi, Z. Kan, Ty Lee, C. Charnsangavej
  4. Copper Chelation Inhibits Endothelial Proliferation in Vitro
    Mary Sproull, Tamalee Scott, Cynthia Menard, Martin Brechbiel, Kevin Campahusen
  5. TEM Expression in Cultured Endothelial Cells
    Beverly A. Teicher, Jennifer Walter-Yohrling, Rebecca Bagley, Cecile Rouleau, Mariana Nacht, Wen Zhang, Srinivas Shankara, Katherine Klinger, Bruce Roberts
  6. Highly Efficient Naked DNA Delivery of a Soluble Form of Vascular Endothelial Growth Factor (VEGF) Receptors (Flt-1 and Flk-1) Gene Suppressed the Growth of Murine Renal Cell Carcinoma
    Hiroshi Yazawa, Suzuki Yasuhiro, Lynnete Shorts, Eilene Grays, Robert H. Wiltrout, Morihiro Watanabe


  1. Anti-RLIP76 IgG Causes Apoptosis in Lung Cancer Cells and Synergistically Increases Anthracycline Cytotoxicity
    Sanjay Awasthi, Sharad S. Sighal
  2. In-Vitro Evaluation of Anti-Ep-CAM Immunocytokine KS-IL2 in Ovarian Cancer
    Joseph P. Connor, Mildred Felder, Jackie Hank, Steve Gillies, Paul Sondel
  3. Tumor Specific Antibodies from Breast Tumor Infiltrating B Cells
    Julia A. Coronella-Wood, Michelle Maly, Evan M. Hersh
  4. The Pre-Clinincal Development of Two Novel Functional Monoclonal Antibodies Demonstrating Anti-Tumor Potential Against Breast Cancer
    Jean De Sousa-Hitzler, S. Hahn, V. Saldivia, F. McConkey, T. Groves, S.W. Fung, L. Martin, D.S. Young
  5. Opsonization with Specific Antibodies Enhances Dendritic Cell Presentation of Apoptotic Tumor Cells and Induction of CTL
    Hubert Eng, Michelle Kuzma, Kate Agopsowicz, Christopher Zarozinski, Birgit C. Schultes
  6. Therapeutic Application of an Anti-CD80 Antibody (IDEC-114) in B-Cell Lymphoma
    K. Hariharan, L.G. Berquist, T. Murphy, N. Hanna, G.R. Braslawsky, B.R. Leigh
  7. Generation of a Human Anti-Heparanase Monoclonal Antibody for Anti-Cancer Therapy
    Steve Holmes, S. Mason, P. Brams
  8. Clinical and Immunological Investigation of the Immunocytokine EMD 273063 (hu14.18-IL2) in Subjects with Metastatic or Recurrent Melanoma
    David King, Mark Albertini, Heidi Schalch, Jacquelyn Hank, Jean Surfus, Jacek Gan, Joan H. Schiller, David Mahvi, Kyungmann Kim, Ralph Reisfeld, Thomas Dahl, Oscar Kashala, Knut Sturmhoefel, Stephen Gillies, Paul Sondel
  9. Pharmacokinetics and Pharmacodynamics of IDEC-152 Antibody in Chimpanzees after Multiple Subcutaneous Doses
    Be-Sheng Kuo, Ken R. Wey, Janet K. Clark, Ann Phan, John E. Leonard
  10. A Chemokine Fusion Protein (LEC/chTNT-3) in Solid Tumor Immunotherapy
    Jiali Li, Peisheng Hu, Leslie A. Khawli, Alan L. Epstein
  11. IDEC-152 (Anti-CD23) as a Potential Therapy for Chronic Lymphocytic Leukemia
    Nuzhat Pathan, Kandasamy Hariharan, Loic Scales, Peter Chu, Michael Hopkins, Alan Saven, Paul Grint, Bryan Leigh
  12. A Newly Established Human Monoclonal Antibody, HMOCC-1 Recognizes Ovarian Cancer Cells
    Nao Suzuki, D. Aoki, K. Tsukazaki, N. Susumu, M. Sakayori, K. Orikawa, M. Mukai, I. Ishida, S. Nozawa
  13. Various Immunostimulatory CpG Oligodeoxynucleotides Enhance the Anti-Tumor Activity Mediated by Antibodies by Activating Different Effector Cell Populations Including CD64 Expressing Cells
    Heidi van Ojik, Ch.E. Dahle, L. Bevaart, J. Bakker, M.J.H. Jansen, M.J. van Vugt, J.G.J. van de Winkel, G.J. Weiner
  14. Phase I Trial of Bispecific Antibody MDX-H210 (FcãRI x HER-2/neu) Up to High Doses in Combination with G-CSF in Patients with Metastatic Breast Cancer
    Heidi van Ojik, R. Repp, Th. Valerius, G. Groenewegen, G. Wieland, Y. Deo, J.G.J. van de Winkel, J.R. Kalden, N. Lang, M. Gramatzki


  1. Evidence for Paracrine Stimulation of Tumor Cell Survival during Pre-Angiogenic Phases of Growth
    Mark Dewhirst, Siqing Shan, Benjamin Moeller, Nicole Robson, Mariano Garcia-Blanco, Christopher Kontos
  2. Interferon-a2b Exhibits Pleiotropic Immunomodulatory and Antitumor Effects in Metastatic Melanoma Leading to Apoptosis
    John Giannios, Emmanuel Michailakis
  3. Altered Cytokine Production in Mice Lacking the Thymidine Phosphorylase Gene
    Misako Haraguchi, Hiroki Yoshida, Hiromitsu Hara, Shinjiro Hamano, Shin-ichi Akiyama
  4. Differential Effect of IL-6 on Response to Oxidative Stress by Colorectal Carcinoma
    John Jessup, R. Samara, S. Lin
  5. Induction of Complete Tumor Regression by IL-12 in a Novel Orthotopic Model of Murine Neuroblastoma: Potential Role of Tumor and/or Endothelia Cell Apoptosis
    Tahira Khan, Julie Hixon, Jim Stauffer, Erin Lincoln, Tim Back, Jon M. Wigginton
  6. IL-12 Immunotherapy of Ovarian Cancer: Direct Upregulation of Fasl and Apoptosis Resistance in Human Ovarian Carcinoma Cell Lines
    Anna Lokshin, Eliezer Gorelik, Adele Marrangoni, Matthew Winans, Robert Edwards
  7. NK Cells are a Source of Dendritic Cell-Mediated Immunoregulation: Two-Signal Requirement for NK Cells to Activate and Polarize DC
    Robbie Mailliard, Y. Son, R. Redlinger, A. Giermasz, P. Kalinsk
  8. Induction of Anti-B16 Melanoma Responses in Mice by Albuleukin (TM), an Interleukin-2 (IL-2) / Human Serum Albumin Fusion Protein
    Robert Melder, Q. Wang, J. Lu, S. Bao
  9. Nonviral Genetic Transfer of Fas Ligand in Combination with Cisplatin Induced Significant Growth Suppression in Prostate Cancer in Vivo
    Hiroyuki Nakanishi, Osam Mazda, Etsuko Satoh, Hiroyuki Morioka, Masahiro Nakao, Yoichi Mizutani, Jiro Imanishi, Tsuneharu Miki
  10. Genomic and Proteomic Profiling of PBMC and Tumor Microenvironment Following Stimulation with High Doses IL-2
    Monica C. Panelli, Brian Martin, Dirk Nagorsen, Ena Wang, Kina Smith, Francesco M. Marincola
  11. Activity of Inpatient Interleukin-2 in Patients with Melanoma or Kidney Cancer Unresponsive to Outpatient Interleukin-2
    Walter Quan, Jr., F.M. Quan
  12. Outpatient Bolus Interleukin-2 in Kidney Cancer and Melanoma
    Walter Quan, Jr., F.M. Quan
  13. Analysis of Serum Antibodies Present in Melanoma Patients Treated with Autologous Tumor Vaccine
    Patric Schiltz, S.H. Hendry, C.C. Malone, R.O. Dillman
  14. Anti-Tumor Effects of Highly Efficient Systemic Interleukin-12 Gene Delivery in Murine Renal Cell Carcinoma
    Morihiro Watanabe, J. Ortaldo, T. Back J. Subleski, H. Yazawa, H. Suzuki, E. Parsoneault, V. Thillainathan, V. Vasquez, L.H. Shorts, R.H. Wiltrout
  15. IL-12 cDNA Direct Injection into Tumor-Bearing or Non-Involved Spleen Results in a Similar Antimetastatic Effect
    Sharon Weber, Chen Qi, Zane Neal, Paul Sondel, David Mahvi
  16. A Phase I Investigation of IL-12/Pulse IL-2 in Adults with Advanced Solid Tumors
    Jon Wigginton, Maureen Edgerly, Peter Choyke, Robert Wiltrout, John Janik
  17. Antitumoral Effects of Cationic Multilamellar Liposomes Containing Human Interferon-ƒÀ Gene against Human Renal Cell Carcinoma
    Kosuke Yamamoto, Hiroyuki Nakanishi, Yoichi Mizutani, Manabu Hatano, Masaaki Mizuno, Jun Yoshida, Tsuneharu Miki
  18. Effect of Low-Dose Interleukin-2 Therapy on Clinical Toxicities and on Th2/Th1 Balance in Melanoma Patients Treated with Melanoma Peptide Vaccine
    Galina Yamshchikov, William Chad Cragun, Elisabeth M. H. Woodson, Kimberly A. Chianese-Bullock, Eric Bissonette, Catherine J. Wiernasz, Gina R. Petroni, Craig L. Slingluff, Jr.

Engineered T Cells

  1. Autologous Peripheral Blood Lymphocytes and Cimetidine as Treatment of Metastatic Renal Cell Cancer, Colorectal Cancer, and Other Solid Tumors
    Robert O. Dillman, P.M. Schiltz, C. de Leon, C. DePriest, G. Soori, A.A. O’Connor, L.D. Beutel, S.K. Nayak
  2. Ex Vivo Generation of Potent Cytotoxic T Lymphocytes for the Treatment of Cancer: A Novel Antigen Presentation System
    Didier J. Leturcq, J.M. Richards, M.R. Jackson, P.A. Peterson, A.M. Moriarty
  3. Treatment of Advanced Malignant Melanoma with Ex Vivo-Generated Autologous T Cells with Specificity for Melanoma-Associated Target Antigens
    Jon M. Richards, M. Genge, L.A. Barbour, D.L. Leturcq, A.M. Moriarty, M.R. Jackson, P.A. Peterson
  4. Single Activation Protocol Improves Vaccine-Primed T Cell Anti-Tumor Activity
    Jeffrey Sussman, R. Parihar, F.D. Finkelman

Immune Monitoring

  1. Analytical Precision and Lot-to-Lot Variability of iTAg™MHC-Tetramer Detection of Antigen-Specific CD8+ Cells and Longitudinal Biological Variability of CMV Antigen-Specific Tetramer+ CD8+ Cells in Healthy Individuals
    Christopher Boyce, D.L. Broyles, J.S. Chamberlin, C.A. Johnson, N.T. Nguyen, S.L. Schubert, L.R. Lofaro, K.R. Bray
  2. Characterization of CD8 Negative, HLA Class I/Epitope Tetrameric Complexes Binding T Cells
    Dirk Nagorsen, Vladia Monsurrò, Ena Wang, Francesco M. Marincola
  3. Generation of iTAg™Tetramer-Binding, CD8 T Cells Using Antigen Presenting Cells Derived from PBMC under Different Culture Conditions
    Janice Payne, April Simora, Kristine Kuus-Reichel, Jennie Chang
  4. Granzyme B ELISPOT Assay as an Alternative to the 51Cr-Release Assay for Immunological Monitoring
    Kimberly Shafer-Weaver, E.G. Derby, M.W. Baseler, A.M. Malyguine

New Therapies/Novel Agents

  1. RNA Replicons Derived from Poliovirus are Directly Oncolytic in a Wide Array of Human Cancer Cells and Extend Survival of Mice Bearing Human Tumors
    David C. Ansardi, Donna C. Porter, Casey D. Morrow, Cheryl Jackson, G. Yancey Gillespie
  2. Treatment of Cancer by Direct Intra-Tumor Injection of Granulocyte/Monocyte-Colony Stimulating Factor
    Stephen Brooks, H. Takita, K. Shin, S. Sharma, Y. Fang, C. Karakousis
  3. Cytokines Mediated Regulation of Heat Shock Protein gp96
    Yuangen Chen, B.T. Ashok, V.P.S. Garikapaty, A. Mittelman, R.K. Tiwari
  4. Antitumor Potential of IL-2 Activated Cord Blood
    Stanka Derzic, V. Slone, M. Schwartz, L. Sender
  5. Cytotoxic T Lymphocyte Recognition of a Her-2/Neu-Derived Peptide Modified at HLA-A*0201 Anchor and Auxiliary Residues
    Sara Dionne, Douglas Lake
  6. Induction of Tumor-Reactive CTL by C-Side Chain Variants of the CTL Epitope HER-2 (369-377) Selected by Molecular Modeling of the Peptide: HLA-A2 Complex
    Clay Efferson, N.E. Ward, K. Kawano, A.P. Kudelka, C.A. O’Brian, C. G. Ioannides, J.L. Murray
  7. Improved Therapy of Chemotherapeutic Drugs in Experimental Solid Tumors by Pretreatment with NHS76/PEP2, a Vascular Enhancing Agent
    Alan Epstein, L.A. Khawli, P. Hu
  8. Oncogenes which Drive the Angiogenic Switch Provide a General Strategy for Discoverying Indirect Angiogenesis Inhibitors
    Judah Folkman
  9. Eradication of Chemoresistant Aneuploid Metastatic Pancreatic Carcinoma Overexpressing CyclinD1, K-Ras and HER-2/Neu after Chemogene Treatment Consisting of Recombinant Replication Defective Adenovirus-p27 and Docetaxel
    John Giannios
  10. Interferon-a2b & Doxycycline Activate Mitochondrial Pathway, DR-5 & Fas, Downregulate EGFR,MMP,bFGF & VEGF, Reduce S-100B,TA-90, AP, Ca, Hydroxy-Proline & Hyaluronidase Inducing Apoptosis in Stage IV Malignant Melanoma Metastasized to Proximal End of Femur
    John Giannios, Emmanuel Michailakis
  11. An Antibody to DR5 (Trail-Receptor 2) Suppresses the Growth of Patient Derived Gastrointestinal Tumors Grown in Scid Mice
    Bonnie Hylander, R. Pitoniak, K. Sugamura, B. Gliniak, D. Lynch, D. Liebowitz, E.A. Repasky
  12. MHC Class II Inducibility is Rescued in Noninducible LS1034 Colon Carcinoma Cell Line by Bryostatin I and Sodium Butyrate
    Yuri Kudinov, C.L. Wiseman, A.I. Kharazi
  13. Increased Ability of Allogeneic NK Cells in the Purging of Leukemic Cells without Impairment of Reconstitution after Syngeneic Bone Marrow Transplantation
    William Murphy, Crystal Koh
  14. Thermal Regulation of Dendritic Cell Activation and Migration
    Julie Ostberg, R. Patel, E. Kabingu, E.A. Repasky
  15. Novel Recombinant Bispecific Molecules for Immunotherapy of B Cell Tumors
    Uwe Reusch, F. LeGall, B. Cochlovius, G. Moldenhauer, M. Little, S. Kipriyanov
  16. Characterization of Surface Markers on Dendritic Cells Used to Support a Phase I/II Trial of Active Specific Immunotherapy for Metastatic Renal Cell Carcinoma Patients
    Patric Schiltz, K.S. Spencer, J.D. Novak, L.D. Beutel, R.O. Dillman
  17. Immunomodulatory Effects of Combination Therapy with Histamine Dihydrochloride and Interleukin-2 During a Phase II Study in Stage IV Melanoma
    Theresa Whiteside, William Gooding, Elaine Elder, Laura Stover, John Glaspy, Kelly McMasters, Albert Deisseroth, Kristoffer Hellstrand, Peter Naredi, Kurt Gehlsen, Steven O’Day, Sanjiv Agarwala
  18. Tumor Expression of 4-1BB Ligand: Sustenance for Tumor-lytic CD8+T Cells?
    Hua Zhang, Melinda S. Merchant, Kevin S. Chua, Elaine K. Thomas, Carl H. June, Crystal L. Mackall


  1. Helper-Dependent Adenovirus Produce Superior Transgene Expression in Human Dendritic Cells, but Still Stimulate Antiviral Immune Responses
    Sylvia Kiertscher, M.D. Roth, Q. Cheng, A. Harui, S.K. Basak, K. Mitani, T.A. Low
  2. A Replication Competent Dual-Ad Vector for Treatment of Prostate Cancer
    Larisa Lillegren, Erica Podar, Lei Huang, Yanchun Lou, Steven Josephs, Elena Prokopenko, Brad Grimm, William McBride, Robert E. Sobol, Yawen L. Chiang, William C. Raschke
  3. Comparison of 3 Different Methods for the Quantification of Circulating Tumor Cells in Blood of Patients with Epithelial Cancers
    Andreas Obwaller, Gottfried Himmler, Bernhard Peball, Philipp Oberkleiner, Hans Loibner, Thomas Bauernhofer, Hellmut Samonigg, Susanne Grunt
  4. Alternatively Spliced Isoforms Yield Novel Epitopes for mAb Therapy
    Matthew Pando, M. Reff, H. Jordan, M. Brenner, G. Levinson, V. Kotraiah, F. Maurier, F. Coignard, B. Brinkman, K. McGowan, R. Einstein
  5. Culture of T Cells from Pts with Renal Cell Carcinoma (RCC) with rhIL-2 Improves Redirected Cytotoxicity when Compared to Normal Donors
    Christopher Tretter, T. Crocenzi, M. Waugh, J. Fisher, B. Cole, D. Truman, N. Crosby, J. Heaney, M.S. Ernstoff
  6. Interferon-Alpha Induced Depression: Research on Pathophysiological Mechanisms
    Arthur R. Van Gool, H.H. van Ojik, W.H.J. Kruit, M. Bannink, A.M.M. Eggermont, J.W. Gratama, T.L.M. Ten Hagen, M. Maes, R. van der Holt, M.W. Hengeveld, G. Stoter, D. Fekkes

Vaccines & Mechanisms

  1. MAGE-1, a Cancer-Testis Antigen, Expression in Childhood Astrocytomas as an Indicator of Tumor Progression
    Bela Bodey, Stuart E. Siegel, Hans E. Kaiser
  2. Rational Design of Completely Synthetic Liposomal Vaccines for Modulating Cellular and Humoral Immune Responses
    Vlad Budzynski, M. Krantz, R. Koganty
  3. Recombinant Mycobacterial Vaccines for Cancer: Alternate Route of Ag-Processing to MHC Class-I in Dendritic Cells
    Eleanor J. Cheadle, Peter J. Selby, Andrew M. Jackson
  4. Human Melanoma Cells May Proliferate after High-Dose Gamma-Irradiation: Guidelines for Safety Considerations in Preparing Autologous Tumor Cell Vaccines
    Donna Deacon, Erin Swanson, Kim Bullock, Craig L. Slingluff, Jr.
  5. Early Results with a Vaccine of Cultured Autologous Tumor Cells and Dendritic Cells in Metastatic Melanoma and Renal Cell Cancer
    Robert O. Dillman, R.S. Selvan, P.M. Schiltz, C. de Leon, C. Peterson, K. Spencer, A. Beatty, C. DePriest, L.D. Beutel
  6. Development of a Clinical Grade Production Process for a Melanoma Vaccine Based on Dendritic Cells Loaded with Allogeneic Tumor Cell Lysates as Antigen Source
    Marie-Therese Duffour, Paula Doceur, Isabelle Chauvet, Catherine Bardon-Defaye, Alessandra Nardin, Farad Heshmati, Jean-Pierre Abastado, Margarita Salcedo
  7. Optimization of Antigen Load Schedule to Generate Mature DCs
    Nina Garlie, Eric Aoys
  8. Active and Protective Immunity Induced by a Protein Based Vaccine Targeting the HER2/Neu Oncogenic
    Catherine Gerard, Mac Cheever, Nathalie Baudson, Terry Foy
  9. Tumor-Derived Chaperone-Rich Cell Lysates Activate Dendritic Cells and Elicit Therapeutic Immunity against a Wide Variety of Cancers
    Michael Graner, Y. Zeng, H. Feng, E. Katsanis
  10. Immunization of Melanoma Patients with Melan-A Peptide-Pulsed PBMC + rhIL-12 Induces Clinical Activity and Increased T Cell Responses: Lack of Correlation between T Cell Frequencies and Clinical Outcome
    Helena Harlin, Amy Peterson, Chris George, Thomas F. Gajewski
  11. Characterization of Heteroclitic Analogs of Tumor-Associated CTL Epitopes Restricted by HLA-A3, -A24, and -B7
    Glenn Ishioka, X. Huang, A. Sette, J. Fikes
  12. Rat and Human Glioma Cells Expressing the Membrane Form of Macrophage Colony Stimulating Factor (mM-CSF) are Killed in Animals via Paraptosis that is Associated with Increased Expression of 3 Different Heat Shock Proteins
    Martin Jadus, Y. Chen, M. Boldaji, C. Delgado, R. Sanchez, T. Douglass, U. Al-Atar, W. Schulz, E.W.B. Jeffes
  13. Induction of Specific Anti-Tumor Immunity with an Electrofusion Product between Tumor Cells and Dendritic Cells
    Johanne Kaplan, K.L. Vergilis, J. Shields, C. Johnson, M. Vasconcelles, W.M. Siders
  14. Induction of Myeloid Leukemia-Derived Antigen Presenting Cells by Retinoic Acid and CD40-Ligand
    Kazunori Kato, Satoshi Takahashi, Hirofumi Hamada
  15. Low Thymic Output and/or Rapid Lymphocyte Turnover in the Circulation of Patients with Head and Neck Cancer
    Iris Kuss, Tony E. Godfrey, Albert D. Donnenberg, Robert L. Ferris, Jeffrey M. Harris, Joseph M. McCune, William Gooding, Theresa L. Whiteside
  16. Vaccination with Alum-Adsorbed Antibodies against EpCAM Directly Induces Anti-EpCAM Antibodies
    Hans Loibner, Manfred Schuster, Gottfried Himmler
  17. AdCD40L Immunogene Therapy Counteracts IL10 Induced Anergy
    Angelica Loskog, Helena Dzojic, Sofia Vikman, Thomas Totterman
  18. Potential Epitopes for Anti-Idiotype Vaccination for T-ALL: Childhood T-ALL Exhibit Complex T-Cell Receptor Gene Rearrangements
    David Margolis, James Casper, Teresa Janczak, Laura McOlash, Bryon Johnson
  19. HIV Immunogens Delivered in an Adenoviral Vaccine Vector Elicit Strong Cellular Immune Responses
    Girija Muralidhar, Manjula Navaratnam, Larisa Lillegren, Mangala Hariharan, Yawen L. Chiang, Robert E. Sobol, Sybille L. Sauter
  20. Antigen Presentation by Mature or Immature Dendritic Cells Infected with Recombinant Vaccinia-Virus
    Dirk Nagorsen, Monica Panelli, Mark E. Dudley, Steven A. Rosenberg, Francesco M. Marincola
  21. Hu14.18-IL2 Immunocytokine Plus Systemic IL-2 Combinatorial Therapy: Prevention of Tumor Escape
    Zane Neal, Alexander Rakhmilevich, Jacquelyn Hank, Holger Lode, Ralph Reisfeld, Stephen Gillies, Paul Sondel
  22. A Validated Computer Model of the Cell-Mediated Responses to Vaccine Therapy of Three Tumors Systems in the C57B/6 Mouse
    Ami Radunskaya, Lisette dePillis, Charles Wiseman
  23. Vaccine-Induced CD8+ T Cell Responses to MAGE-3 Correlate with Clinical Outcome in Patients with Melanoma
    Sandra Reynolds, A.Z. Jacquotte, R.L. Shapiro, D.F. Roses, M.N. Harris, D. Johnston, J.C. Bystryn
  24. Identification and Immunotherapy of T-Cell Defined Tumor-Specific Epitopes in Recoverin, SYT-SSX Chromosomal Translocation Protein and a New Transcription Protein
    Noriyuki Sato, T. Torigoe, S. Kawaguchi, T. Tsukahara, Y. Nabeta, K. Ida, Y. Sato, A. Maeda, H. Ohguro, T. Yamashita, H. Ikeda
  25. Generation of Cultured Autologous Tumor Cells for Tumor Cell-Pulsed Dendritic Cell Vaccines in Human Metastatic Melanoma and Renal Cell Cancer
    Rathinam Selvan, A. Beatty, J. Novak, K. Spencer, B.W. Brown and R.O. Dillman
  26. Establishment of Human Renal Cell Carcinoma Cell Lines for Generating Autologous Tumor Cell Vaccine: Overcoming Major Limiting Factor of Outgrowth of Normal Epithelial Cells in Tumor Tissue Culture
    Rathinam Selvan, B.W. Brown, S. Ravi, F.S. Heinemann, N. Rao, R.O. Dillman
  27. Clinical and Immunological Evaluation of Hormone-Refractory Prostate Cancer Patients Treated with DCVax™Prostate in a Phase I/II Trial
    Gopi Shankar, Heather Kelley, Linda Samadzadeh, Anne Lodge, Alton Boynton, Christos Papandreou, Christopher Logothetis, Arie Belldegrun, Abdel Aziz Elgamal
  28. Functional Reactivity of Circulating T-Cells which Recognize Melanoma-Associated Antigens from Normal Donors and Peptide-Immunized Patients
    Manish Sharma, Peter P. Lee, James J. Mule’, Jeffrey S. Weber
  29. CpG 7909 a Promising Adjuvant to Vaccination with MAGE-3 Protein in Patients with MAGE-3 Positive Tumors Results of a Phase I/II Study
    Heidi H. van Ojik, W.H.J. Kruit, J. P. Portielje, V. Brichard, R. Verloes, M. Delire, G. Stoter
  30. Development of Tumor-Specific Immunotherapy Targeting IAP Family Proteins
    Toshihiko Torigoe, S. Idenoue, Y. Hirohashi, M. Yamamoto, H. Hariu, H. Asanuma, A. Yagihashi, H. Ikeda, N. Sato
  31. Generation of Dendritic Cell-Tumor Cell Hybrids for Clinical Vaccine Application
    Katrina Trevor, Emmanuel Akporiaye, Evan Hersh, Cathleen Cover, Didier Landais, Rachel Taylor, Alan King, Richard Walters
  32. Enhancement of Cytotoxic T Lymphocyte Responses in Patients with Gastrointestinal Malignancies Following Vaccination with CEA Peptide Pulsed Dendritic Cells
    Takuya Tsunoda, Kenji Matsuda, Hiroki Yamaue
  33. Whole-Cell Tumor Vaccine for Human Renal Carcinoma: Preliminary Results in 14 Cases
    Charles Wiseman, A. Kharazi, Y. Kudinov
  34. The Human Papillomavirus 16 E6 Variant L83V Linked to Human Leukocyte Antigen B*51 is Associated with Higher Frequency of Cervical Cancer
    Ingeborg Zehbe, Joannis Mytilineos, Ingrid Wikstrom, Rudi Hendriksen, Karin Stalberg, Massimo Tommasino
  35. Exogenous Stress Proteins Enhance the Immunogenicity of Apoptotic Tumor Cells and Stimulate Anti-Tumor Immunity
    Yi Zeng, H. H. Feng, M.W. Graner, A. Likhacheva, E. Katsanis